In a report released on September 30, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline, with a price target of p1,580.00. The company’s shares opened today at p1,675.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and UCB SA. According to TipRanks, Sharma has an average return of -2.0% and a 48.75% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for GlaxoSmithKline with a p1,593.85 average price target, a -4.87% downside from current levels. In a report released on September 30, Barclays also maintained a Hold rating on the stock with a £14.50 price target.
The company has a one-year high of p1,672.14 and a one-year low of p1,242.50. Currently, GlaxoSmithKline has an average volume of 7.88M.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- Cautious Outlook on GlaxoSmithKline: Sell Rating Amid Uncertain Future Performance and Competitive Pressures
- Trump Trade: White House announces drug pricing deal with Pfizer
- GSK Announces Total Voting Rights and Capital Update
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- GSK Enhances Shareholder Value with Strategic Buyback
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20logo%20and%20chart%20data-by%20Poetra_%20RH%20via%20Shutterstock.jpg)